NADAC acquisition cost data for RISPERIDONE 0.25 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00904635761 | $0.0419 | 2022-12-21 | Rx |
| 13107011905 | $0.0419 | 2022-12-21 | Rx |
| 13668003505 | $0.0419 | 2022-12-21 | Rx |
| 13668003560 | $0.0419 | 2022-12-21 | Rx |
| 27241000206 | $0.0419 | 2022-12-21 | Rx |
| 27241000250 | $0.0419 | 2022-12-21 | Rx |
| 43547033906 | $0.0419 | 2022-12-21 | Rx |
| 43547033950 | $0.0419 | 2022-12-21 | Rx |
| 68084027001 | $0.0419 | 2022-12-21 | Rx |
| 68084027011 | $0.0419 | 2022-12-21 | Rx |
Generic: Risperidone | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $62.1M | 4,172,661 | 541,995 | $0.3002 |
| 2020 | $56.2M | 4,053,304 | 523,532 | $0.2715 |
| 2021 | $56.4M | 3,887,305 | 504,508 | $0.2834 |
| 2022 | $56.3M | 3,811,010 | 490,641 | $0.2891 |
| 2023 | $60.8M | 3,732,647 | 478,904 | $0.3159 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $6.2M | 311,151 | 44,789 |
| New York | $4.7M | 285,384 | 36,232 |
| Florida | $3.9M | 227,993 | 36,965 |
| Pennsylvania | $3.1M | 212,616 | 24,944 |
| Texas | $3.0M | 186,248 | 30,167 |
| Ohio | $2.9M | 165,169 | 20,832 |
| Illinois | $2.3M | 152,520 | 18,868 |
| Massachusetts | $2.1M | 119,759 | 14,968 |
| Michigan | $2.0M | 123,725 | 17,022 |
| New Jersey | $1.9M | 117,565 | 14,960 |
| North Carolina | $1.9M | 109,730 | 15,848 |
| Georgia | $1.5M | 111,855 | 14,635 |
| Washington | $1.4M | 77,987 | 10,119 |
| Virginia | $1.3M | 75,580 | 10,984 |
| Minnesota | $1.3M | 72,605 | 8,265 |
| Indiana | $1.2M | 74,698 | 10,308 |
| Missouri | $1.2M | 81,136 | 9,989 |
| Tennessee | $1.2M | 83,039 | 11,689 |
| Wisconsin | $1.2M | 69,326 | 8,223 |
| Maryland | $1.1M | 65,477 | 8,743 |
| Connecticut | $1.1M | 59,076 | 7,398 |
| Arizona | $1.1M | 62,568 | 9,418 |
| Kentucky | $1.0M | 61,150 | 9,203 |
| South Carolina | $885.5K | 54,233 | 7,734 |
| Puerto Rico | $884.5K | 128,346 | 17,133 |
| Louisiana | $845.3K | 60,119 | 8,576 |
| Alabama | $822.1K | 53,980 | 7,692 |
| Colorado | $815.5K | 44,080 | 6,264 |
| Oregon | $773.8K | 40,402 | 5,707 |
| Iowa | $663.1K | 46,266 | 5,358 |
| Oklahoma | $613.5K | 36,183 | 5,668 |
| Mississippi | $571.9K | 41,949 | 5,677 |
| Kansas | $506.9K | 31,400 | 4,096 |
| Maine | $490.1K | 26,397 | 3,997 |
| Arkansas | $462.4K | 29,274 | 4,309 |
| Nebraska | $419.8K | 24,898 | 2,967 |
| West Virginia | $385.0K | 24,237 | 3,473 |
| Nevada | $374.7K | 23,941 | 4,318 |
| New Hampshire | $346.0K | 18,126 | 2,478 |
| Rhode Island | $288.1K | 18,174 | 2,437 |
| New Mexico | $277.5K | 15,222 | 2,558 |
| Utah | $253.3K | 16,058 | 2,484 |
| Idaho | $221.7K | 15,723 | 2,234 |
| Hawaii | $203.8K | 7,974 | 1,543 |
| Vermont | $181.5K | 10,383 | 1,289 |
| North Dakota | $159.7K | 10,960 | 1,226 |
| Delaware | $157.7K | 9,116 | 1,443 |
| Montana | $152.2K | 9,773 | 1,205 |
| South Dakota | $127.0K | 9,901 | 1,167 |
| Alaska | $113.9K | 5,980 | 624 |
| District of Columbia | $97.9K | 5,648 | 1,111 |
| Wyoming | $58.3K | 3,531 | 510 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.